Literature DB >> 17336619

Nonlinear pharmacokinetics of high-dose recombinant fusion protein CD4-IgG2 (PRO 542) observed in HIV-1-infected children.

Courtney V Fletcher, Jaime G DeVille, Pearl M Samson, John H Moye, Joseph A Church, Hans M L Spiegel, Paul Palumbo, Terence Fenton, M Elizabeth Smith, Bobbie Graham, Joyce M Kraimer, William T Shearer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17336619      PMCID： PMC1910693          DOI： 10.1016/j.jaci.2006.10.045

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  11 in total

Review 1.  Antibody pharmacokinetics and pharmacodynamics.

Authors:  Evelyn D Lobo; Ryan J Hansen; Joseph P Balthasar
Journal:  J Pharm Sci       Date:  2004-11       Impact factor: 3.534

Review 2.  Monoclonal antibodies and fusion proteins in medicine.

Authors:  Stamatis-Nick C Liossis; George C Tsokos
Journal:  J Allergy Clin Immunol       Date:  2005-10       Impact factor: 10.793

Review 3.  Selection, design, and engineering of therapeutic antibodies.

Authors:  Leonard G Presta
Journal:  J Allergy Clin Immunol       Date:  2005-10       Impact factor: 10.793

4.  Susceptibility of pediatric HIV-1 isolates to recombinant CD4-IgG2 (PRO 542) and humanized mAb to the chemokine receptor CCR5 (PRO 140).

Authors:  William T Shearer; Jaime G DeVille; Pearl M Samson; John H Moye; Courtney V Fletcher; Joseph A Church; Hans M L Spiegel; Paul Palumbo; Terence Fenton; M Elizabeth Smith; Bobbie Graham; Joyce M Kraimer; William C Olson
Journal:  J Allergy Clin Immunol       Date:  2006-05-19       Impact factor: 10.793

Review 5.  Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG.

Authors:  R P Junghans
Journal:  Immunol Res       Date:  1997-02       Impact factor: 2.829

Review 6.  The role of cell-surface receptors in the transport and catabolism of immunoglobulins.

Authors:  T A Waldmann; E A Jones
Journal:  Ciba Found Symp       Date:  1972

7.  Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults.

Authors:  J M Jacobson; I Lowy; C V Fletcher; T J O'Neill; D N Tran; T J Ketas; A Trkola; M E Klotman; P J Maddon; W C Olson; R J Israel
Journal:  J Infect Dis       Date:  2000-06-30       Impact factor: 5.226

8.  Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study Team.

Authors:  W T Shearer; R J Israel; S Starr; C V Fletcher; D Wara; M Rathore; J Church; J DeVille; T Fenton; B Graham; P Samson; S Staprans; J McNamara; J Moye; P J Maddon; W C Olson
Journal:  J Infect Dis       Date:  2000-10-27       Impact factor: 5.226

Review 9.  Biologic immune modifiers: Trials and tribulations--are we there yet?

Authors:  Mark Ballow
Journal:  J Allergy Clin Immunol       Date:  2006-10-27       Impact factor: 10.793

10.  Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542.

Authors:  Jeffrey M Jacobson; Robert J Israel; Israel Lowy; Nancy A Ostrow; Linda S Vassilatos; Melanie Barish; Diep N H Tran; Brian M Sullivan; Thomas J Ketas; Tobias J O'Neill; Kirsten A Nagashima; Wei Huang; Christos J Petropoulos; John P Moore; Paul J Maddon; William C Olson
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191
View more
  9 in total

1.  Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains.

Authors:  Weizao Chen; Yang Feng; Ponraj Prabakaran; Tianlei Ying; Yanping Wang; Jianping Sun; Camila D S Macedo; Zhongyu Zhu; Yuxian He; Victoria R Polonis; Dimiter S Dimitrov
Journal:  J Virol       Date:  2013-11-06       Impact factor: 5.103

2.  Engineered single human CD4 domains as potent HIV-1 inhibitors and components of vaccine immunogens.

Authors:  Weizao Chen; Yang Feng; Rui Gong; Zhongyu Zhu; Yanping Wang; Qi Zhao; Dimiter S Dimitrov
Journal:  J Virol       Date:  2011-06-29       Impact factor: 5.103

Review 3.  Engineering broadly neutralizing antibodies for HIV prevention and therapy.

Authors:  Casey K Hua; Margaret E Ackerman
Journal:  Adv Drug Deliv Rev       Date:  2016-01-29       Impact factor: 15.470

4.  AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges.

Authors:  Matthew R Gardner; Lisa M Kattenhorn; Hema R Kondur; Markus von Schaewen; Tatyana Dorfman; Jessica J Chiang; Kevin G Haworth; Julie M Decker; Michael D Alpert; Charles C Bailey; Ernest S Neale; Christoph H Fellinger; Vinita R Joshi; Sebastian P Fuchs; Jose M Martinez-Navio; Brian D Quinlan; Annie Y Yao; Hugo Mouquet; Jason Gorman; Baoshan Zhang; Pascal Poignard; Michel C Nussenzweig; Dennis R Burton; Peter D Kwong; Michael Piatak; Jeffrey D Lifson; Guangping Gao; Ronald C Desrosiers; David T Evans; Beatrice H Hahn; Alexander Ploss; Paula M Cannon; Michael S Seaman; Michael Farzan
Journal:  Nature       Date:  2015-02-18       Impact factor: 49.962

5.  Further Characterization of the Bifunctional HIV Entry Inhibitor sCD4-FIT45.

Authors:  Alexander Falkenhagen; Sadhna Joshi
Journal:  Mol Ther Nucleic Acids       Date:  2017-04-22

Review 6.  Driving HIV-1 into a Vulnerable Corner by Taking Advantage of Viral Adaptation and Evolution.

Authors:  Shigeyoshi Harada; Kazuhisa Yoshimura
Journal:  Front Microbiol       Date:  2017-03-16       Impact factor: 5.640

Review 7.  A Little Help From the Follicles: Understanding the Germinal Center Response to Human Immunodeficiency Virus 1 Infection and Prophylactic Vaccines.

Authors:  Ebony N Gary; Michele A Kutzler
Journal:  Clin Med Insights Pathol       Date:  2017-03-30

Review 8.  Anti-infective immunoadhesins from plants.

Authors:  Keith Wycoff; James Maclean; Archana Belle; Lloyd Yu; Y Tran; Chad Roy; Frederick Hayden
Journal:  Plant Biotechnol J       Date:  2015-08-04       Impact factor: 9.803

Review 9.  Molecular decoys: antidotes, therapeutics and immunomodulators.

Authors:  Jonathan M Gershoni
Journal:  Curr Opin Biotechnol       Date:  2008-11-18       Impact factor: 9.740
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.